Aspivix, a pioneering leader in women’s health, is pleased to announce the appointment of two esteemed professionals, Dr. Susan Nicholson and Jessica J. Federer, to its Board of Directors. This strategic augmentation of the board with their expertise heralds a new era in Aspivix’s commitment to transforming women’s health care.
Dr. Susan Nicholson: Pioneering Transformation and Catalyst for Change
Dr. Susan Nicholson, a science-driven innovator and women’s health champion, joins Aspivix as an independent director and will serve as the chair of the board. With over 25 years of experience in biotech, big pharma, medical devices, and consumer health, Dr. Nicholson brings a wealth of expertise in identifying high-impact healthcare innovation and translating innovative ideas into actionable, patient centric business plans ensuring high-quality and equitable healthcare for women. As the former Vice President of Women’s Health at J&J, her leadership in developing key maternal health digital tools and programs has been instrumental in addressing the root causes of the US maternal mortality crisis.
Jessica J. Federer: Strategic Leader and Industry Convener
Jessica J. Federer, an experienced board member and former Chief Digital Officer of Bayer A.G., also joins Aspivix’s Board of Directors. She is recognized as an icon in digital health and emerging innovations, with a focus on deploying technology for meaningful advancements in business and society.
Jessica is committed to increasing investment in innovations to modernize women’s health.
Keren Leshem
Ms. Leshem, CEO and a Director/Board Member at OCON Healthcare, is a highly accomplished healthcare executive with over 20 years of experience in the medical device industry, including leadership roles in strategy, marketing, and product experience and knowledge of the medical device industry make her an excellent addition to ASPIVIX’s board. She has a proven track record of driving growth and innovation in healthcare companies, and her expertise in product development and marketing will be invaluable as ASPIVIX continues to develop and bring to market innovative medical devices for women’s health.
She currently serves as an independent board member of several medical device companies and is a frequent speaker and panelist at industry events. She has been featured in FORBES magazine as one of 3 women shaping the future of women’s health, been invited to the World Economic Forum as a technology pioneer and named 1 of 100 women of influence by Entrepreneur magazine. Keren is a steering committee member with the NIH – Bill & Melinda Gates Foundation IEF (Innovation Equity Forum), I‘ve joined UK’s FemTech Lab’s admissions and advisory Board as well as LSX’s Advisory Board and I’m a Mentor at the Israeli 8400 Healthtech Network program.
Commenting on her appointment, Ms. Leshem said, “I am thrilled to be joining the board of ASPIVIX at such an exciting time for the company. I have been impressed by the team’s dedication to improving women’s health through innovative medical devices, and I look forward to working with them to achieve their goals.”
Strengthening the Board with Diverse Expertise
The addition of Dr. Nicholson and Jessica J. Federer to Aspivix’s board further strengthens the company’s leadership and positions it for continued success in developing groundbreaking solutions to improve women’s health.
Adding these two experts in Women’s health to a board that includes Keren Leshem, CEO of OCON Therapeutics, underscores Aspivix’s dedication to diverse leadership and innovative thinking. Together, their combined expertise and vision are expected to drive significant advancements in women’s health.
“We are thrilled to welcome Dr. Susan Nicholson and Jessica J. Federer to our Board of Directors,” expressed Mathieu Horras, CEO of Aspivix. “Their wealth of experience, unwavering expertise, and profound commitment to advancing women’s health perfectly resonate with our mission. We look forward to their valuable contributions as we continue to revolutionize women’s healthcare.”
About Aspivix
Aspivix is a pioneering leader in women’s health, dedicated to modernizing healthcare solutions for women around the world. With a focus on innovation, Aspivix is committed to developing cutting-edge medical devices, such as carevix™, which aim to transform the gynecological experience by offering safer and less painful solutions that enhance the quality of care and empower women to take control of their health.
About Carevix™
Carevix™ is a novel cervical suction stabilizer that has been clinically proven to be atraumatic during transcervical procedures. The First-In-Women highly compelling results from the ADVANCE Women (Atraumatic Device using VAcuum Technology for CErvical Procedures in WOMEN), a randomized controlled trial of carevix™, used In IUD Procedures against the cervical tenaculum has been published in “Contraception”, the International Reproductive Health Journal in March 2023.
Carevix™ has received FDA-clearance and CE-Mark approval in 2023 which will allow carevix™ to be available for commercialization in Europe and the United States of America very soon.
